ArticleInternational journal of clinical oncology2026
Clinical experience with de-escalated chemotherapy for a subset of high-risk gestational trophoblastic neoplasia at a single institution.
Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe FIGO scoring system is a well-established method for classifying patients with gestational trophoblastic neoplasia (GTN) worldwide, and the Japanese scoring system is widely employed in Japan. This study aimed to evaluate the clinical outcomes of de-escalated chemotherapy in patients with high-risk GTN, classified as "clinical invasive mole" according to the Japanese scoring system.
methodsWe retrospectively reviewed 268 patients with GTN who received initial treatment at Nagoya University Hospital between 1991 and 2023. All patients were assessed using the FIGO and Japanese scoring systems, and treatment strategies were determined primarily based on histopathological diagnosis and subsequently guided by the Japanese scoring system. Clinical features and treatment outcomes were analyzed.
resultsAmong 268 patients, 49 were classified as having high-risk GTN. All patients with FIGO scores of ≥ 9 were classified as "clinical choriocarcinoma" by the Japanese scoring system. In contrast, 17 patients with FIGO scores of 7-8 were divided into the invasive mole group (n = 7) and the choriocarcinoma group (n = 10). All patients in the invasive mole group received de-escalated chemotherapy and achieved complete remission. The proportions of patients with age ≥ 40 years (p = 0.046), antecedent hydatidiform mole (p = 0.021), shorter interval from index pregnancy (p = 0.002), and larger tumor size (p = 0.003) were significantly higher in the invasive mole group than in the choriocarcinoma group.
conclusionDe-escalated chemotherapy may be feasible for select patients with FIGO scores of 7-8, and further refinement of risk stratification is warranted to avoid overtreatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.